Novel aptamer to von Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and comparable to caplacizumab

Kazuya Sakai, Tatsuhiko Someya, Kaori Harada, Hideo Yagi, Taei Matsui, and Masanori Matsumoto

Disclosures: M.M. is a member of an advisory board of Sanofi. T.S. and K.H. are employees of TAGCyx Biotechnologies, Inc. Other authors declare no competing financial interests.

Contributions: K.S, T.S, K.H, and T.M performed experiments and wrote the paper. H.Y designed the study and analyzed the data. M.M designed the research and wrote the paper.